Benzothiazolyl and Benzoxazolyl Hydrazones Function as Zinc Metallochaperones to Reactivate Mutant p53.
John A GilleranXin YuAlan J BlayneyAnthony F BencivengaBing NaDavid J AugeriAdam R BlandenS David KimballStewart N LohJacques Y RobergeDarren R CarpizoPublished in: Journal of medicinal chemistry (2021)
We identified a set of thiosemicarbazone (TSC) metal ion chelators that reactivate specific zinc-deficient p53 mutants using a mechanism called zinc metallochaperones (ZMCs) that restore zinc binding by shuttling zinc into cells. We defined biophysical and cellular assays necessary for structure-activity relationship studies using this mechanism. We investigated an alternative class of zinc scaffolds that differ from TSCs by substitution of the thiocarbamoyl moiety with benzothiazolyl, benzoxazolyl, and benzimidazolyl hydrazones. Members of this series bound zinc with similar affinity and functioned to reactivate mutant p53 comparable to the TSCs. Acute toxicity and efficacy assays in rodents demonstrated C1 to be significantly less toxic than the TSCs while demonstrating equivalent growth inhibition. We identified C85 as a ZMC with diminished copper binding that functions as a chemotherapy and radiation sensitizer. We conclude that the benzothiazolyl, benzoxazolyl, and benzimidazolyl hydrazones can function as ZMCs to reactivate mutant p53 in vitro and in vivo.
Keyphrases
- oxide nanoparticles
- wild type
- induced apoptosis
- squamous cell carcinoma
- intensive care unit
- structure activity relationship
- liver failure
- signaling pathway
- mass spectrometry
- acute respiratory distress syndrome
- cell death
- cell cycle arrest
- transcription factor
- respiratory failure
- drug induced
- hepatitis b virus
- atomic force microscopy
- aortic dissection